Revenio Group Oyj (HEL:REG1V), a health technology company focussing on ophthalmic products, announced on Monday that it has appointed Mikko Moilanen as the CEO of the company, effective on 5 August 2019.
Timo Hildén, the previous CEO, will continue to lead the integration work of CenterVue acquisition.
Previously, Moilanen was the CEO of Grano Group Oy, owned by the investment company Panostaja Oyj, He also held the position of CEO of Suunto Oy and he has held several international management positions in Nokia Plc.
Revenio Group consists of Icare Finland Oy, Icare USA Inc, Revenio Italy S.R.L, CenterVue SpA, CenterVue Inc, Revenio Research Oy and Oscare Medical Oy.
AbbVie's Allergan Aesthetics announces Natrelle supplier agreement with Vizient
Karyopharm Therapeutics awards inducement grants to new employees
POLYTECH Health & Aesthetics announces Poland expansion
Santhera Pharmaceuticals signs Gulf region distribution agreement with Uniphar
Novo Nordisk expands legal action over compounded 'semaglutide'
Neuraxpharm launches Neuraxpharm Australia
OncoZenge selects Meribel Pharma as CDMO for Phase 3 BupiZenge project
Fridays nominated for World Out of Home awards for weight loss campaign
Physiomics expands into biometrics with two contract wins and new division head